Venous Thrombosis Clinical Trial
Official title:
Arixtra(Fondaparinux) vs. Lovenox (Enoxaparin) in Prevention of DVT in Acute Medically Ill, Non-surgical Patients
A total of 50 patients >40 yrs of age with an expected hospital stay in the Medical Intensive Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer will be enrolled. The patient and study team will be blinded to which drug they are receiving (either Arixtra or Lovenox). Subjects will be examined for any bleeding complications. Subjects will receive drug for a total of 6-14 days while in the hospital. A follow up phone call will be performed by the study team approximately 30 days after discharge from the hospital.
A total of 50 patients will be enrolled in this double-blinded, randomized, controlled trial. Inclusion criteria: subjects>40 yrs of age with an expected hospital stay in the Medical Intensive Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer (4 days bedridden) will be enrolled. Total drug treatment will be 6-14 days while in the hospital. A follow up phone call will be performed by the study team approximately 30 days after hospital discharge. Primary endpoint: bleeding rate (minor vs major) between study days 1-14. Secondary endpoint: DVT study days 1-14 (confirmed with LE duplex ultrasonogram). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02567903 -
Tourniquet Study: A Clinical Trial Into the Effect of Tourniquet Use on the Coagulation System
|
N/A | |
| Completed |
NCT02247414 -
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
|
Phase 4 | |
| Recruiting |
NCT02650453 -
Ongoing Registry of Deep Venous Reconstructions
|
N/A | |
| Completed |
NCT00839657 -
Clarification of Optimal Anticoagulation Through Genetics
|
Phase 3 | |
| Completed |
NCT02065388 -
Pharmacogenetic Dosing of Warfarin
|
Phase 3 | |
| Terminated |
NCT00872079 -
Personalized Warfarin Dosing by Genomics and Computational Intelligence
|
N/A | |
| Completed |
NCT02892565 -
Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)
|
N/A | |
| Completed |
NCT00346424 -
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
|
Phase 3 | |
| Active, not recruiting |
NCT04349189 -
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
|
||
| Recruiting |
NCT02238444 -
Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy
|
Phase 4 | |
| Recruiting |
NCT02597218 -
Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.
|
||
| Completed |
NCT00986154 -
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
|
Phase 3 | |
| Completed |
NCT00246025 -
A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.
|
Phase 2 | |
| Completed |
NCT00097357 -
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
|
Phase 2/Phase 3 | |
| Completed |
NCT04645550 -
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
|
Phase 4 | |
| Recruiting |
NCT02264743 -
Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy
|
Phase 4 | |
| Completed |
NCT01482273 -
Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis
|
N/A | |
| Recruiting |
NCT01252420 -
Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis
|
Phase 4 | |
| Completed |
NCT01145859 -
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
|
Phase 1 | |
| Completed |
NCT00790335 -
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
|
Phase 3 |